This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)

This study is currently recruiting participants.
See Contacts and Locations
Verified April 2017 by ACADIA Pharmaceuticals Inc.
Information provided by (Responsible Party):
ACADIA Pharmaceuticals Inc. Identifier:
First received: December 12, 2016
Last updated: April 18, 2017
Last verified: April 2017
To evaluate the efficacy of pimavanserin compared with placebo in treatment of agitation and aggression after 12 weeks of treatment

Condition Intervention Phase
Agitation and Aggression in Alzheimer's Disease Drug: Pimavanserin 34 mg Drug: Pimavanserin 20 mg Other: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease

Resource links provided by NLM:

Further study details as provided by ACADIA Pharmaceuticals Inc.:

Primary Outcome Measures:
  • Cohen-Mansfield Agitation Inventory (CMAI) [ Time Frame: Approximately 12 weeks ]
    Change from Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) total score

Estimated Enrollment: 432
Study Start Date: November 2016
Estimated Study Completion Date: July 2019
Estimated Primary Completion Date: June 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pimavanserin 34 mg
Drug- pimavanserin tartrate, 34 mg, taken as two 17 mg tablets, once daily by mouth
Drug: Pimavanserin 34 mg
Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
Experimental: Pimavanserin 20 mg
Drug- pimavanserin tartrate, 20 mg, taken as two 10 mg tablets, once daily by mouth
Drug: Pimavanserin 20 mg
Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth
Placebo Comparator: Placebo
Placebo, taken as two tablets, once daily by mouth
Other: Placebo
Placebo, taken as two tablets, once daily by mouth


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female, 50 years of age or older
  2. Must be able to understand and provide signed informed consent

    • from patient, if capable of giving consent
    • from patient's Legally Authorized Representative (LAR) if patient is not capable of giving consent.
  3. Has a diagnosis of probable AD according to the National Institute on Aging-Alzheimer's Association (NIA-AA) guidelines
  4. Meets criteria for agitation according to the International Psychogeriatric Association (IPA) guidelines
  5. Lives at home or in an assisted living facility (but can visit the clinic as an outpatient). Subjects must have been at their current location for at least 3 weeks prior to Screening and plan to remain at the same location for the duration of the trial.
  6. Has a designated study partner/caregiver who is in contact with the patient at least 3 times a week on 3 separate days
  7. Female patients must be of non-childbearing potential or must agree to use an acceptable method of contraception or abstinence , for at least 1 month prior to randomization, during the study, and 1 month following completion of the study
  8. The patient and caregiver are willing and able to participate in all schedule evaluations and complete all required tests

Exclusion Criteria:

  1. The agitation/aggression is attributable to concomitant medications, environmental conditions, substance abuse, or active medical or psychiatric condition
  2. Treatment with an antipsychotic medication within 2 weeks of Baseline visit or 5 half lives, whichever is longer
  3. Patient or study partner/caregiver has a medical condition (e.g., hearing, vision impairments) that would impair the ability to perform the study assessments.
  4. Has had a myocardial infarction within the last six months
  5. Has a history or symptoms of long QT syndrome
  6. Has a history of a significant psychotic disorder before or during the diagnosis of probable Alzheimer's disease (including, but not limited to schizophrenia or bipolar disorder)
  7. Patient is bedridden or has any significant medical condition that is unstable and would place the patient at undue risk from study drug or study procedures Has a sensitivity to pimavanserin or its excipients
  8. Has previously participated in a clinical study with pimavanserin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02992132

Contact: James M. Youakim, MD 858-261-2981
Contact: J. Patrick Kesslak 858-320-8699

United States, California
Costa Mesa, California, United States, 92626
Fresno, California, United States, 93710
Fullerton, California, United States, 92835
Pasadena, California, United States, 91105
San Diego, California, United States, 92103
United States, Connecticut
Danbury, Connecticut, United States, 06810
United States, Florida
Naples, Florida, United States, 34102
United States, Michigan
Clinton, Michigan, United States, 48035
United States, Mississippi
Madison, Mississippi, United States, 39110
United States, New Jersey
Eatontown, New Jersey, United States, 07724
Toms River, New Jersey, United States, 08755
United States, North Carolina
Charlotte, North Carolina, United States, 28270
United States, Texas
DeSoto, Texas, United States, 75115
United States, Washington
Spokane, Washington, United States, 99202
Sponsors and Collaborators
ACADIA Pharmaceuticals Inc.
  More Information

Responsible Party: ACADIA Pharmaceuticals Inc. Identifier: NCT02992132     History of Changes
Other Study ID Numbers: ACP-103-032
2016-001127-32 ( EudraCT Number )
Study First Received: December 12, 2016
Last Updated: April 18, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Alzheimer Disease
Psychomotor Agitation
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Neurologic Manifestations
Psychomotor Disorders
Neurobehavioral Manifestations
Signs and Symptoms
Behavioral Symptoms
Antiparkinson Agents
Anti-Dyskinesia Agents
Serotonin 5-HT2 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on August 17, 2017